A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
Starting soon · Phase 2 · Has a placebo group
Conditions studied: Adult Participants With Elevated Lipoprotein(a)
In brief
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
Key facts
- Study ID
- NCT07640217
- Run by
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- People needed
- 120
- Starts
- 2026-07-30
- Expected to finish
- 2028-09-30
- Last updated by the study team
- 2026-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female participants ≥18 years of age;
- Elevated Lp(a);
- Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs;
- Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk;
- Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.
You may not qualify if…
- Diseases that significantly affect Lp(a) during screening period,
- Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization;
- Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period;
- NYHA class III-IV at the time of signing the ICF or LVEF <40% during the screening period;
- Type 1 diabetes or hereditary hemorrhagic disorder at screening;
- History of malignant tumor or suspected malignancy within 5 years prior to screening;
- Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period;
- Allergy to oligonucleotide drugs;
- Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug;
- Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.